nasdaq:clvs
|
904367
|
Mar 24th, 2024 12:00AM
|
Clovis Oncology
|
20K
|
89.00
|
Open
|
|
Mar 24th, 2024 12:18AM
|
Mar 24th, 2024 12:18AM
|
Clovis Oncology is advancing the fight against cancer.
Founded in 2009, Clovis Oncology is a commercial-stage biotechnology company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Our pursuit is to improve the lives of people living with cancer. We believe our approach to precision medicine—to deliver the right drug to the right patient at the right time—represents the future of cancer therapy.
Our product development programs generally target specific subsets of cancer, and we seek to simultaneously develop, with partners, for those indications that require them, diagnostic tools intended to direct a compound in development to the patients most likely to benefit from their use. Through these collaborations, we have the flexibility to choose the most appropriate technology for each program, and the expertise to gain regulatory approvals and support global commercialization that will parallel Clovis’ regulatory and commercialization paths.
Clovis Oncology’s management team has extensive experience in the development of novel cancer therapies and a shared commitment to the company’s vision for meaningful improvements in the lives of patients with cancer.
Clovis Oncology (NASDAQ: CLVS) is headquartered in Boulder, Colorado.
Please visit our website for more information, including additional office locations in the U.S. and Europe.
|
Open
|
oncology drug development and biotechnology
|
Open
|
5500 Flatiron Parkway
|
Boulder
|
CO
|
US
|
80301
|
|
Clovis Oncology
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:clvs
|
904367
|
Mar 23rd, 2024 12:00AM
|
Clovis Oncology
|
20K
|
89.00
|
Open
|
|
Mar 22nd, 2024 11:19PM
|
Mar 23rd, 2024 06:33PM
|
Clovis Oncology is advancing the fight against cancer.
Founded in 2009, Clovis Oncology is a commercial-stage biotechnology company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Our pursuit is to improve the lives of people living with cancer. We believe our approach to precision medicine—to deliver the right drug to the right patient at the right time—represents the future of cancer therapy.
Our product development programs generally target specific subsets of cancer, and we seek to simultaneously develop, with partners, for those indications that require them, diagnostic tools intended to direct a compound in development to the patients most likely to benefit from their use. Through these collaborations, we have the flexibility to choose the most appropriate technology for each program, and the expertise to gain regulatory approvals and support global commercialization that will parallel Clovis’ regulatory and commercialization paths.
Clovis Oncology’s management team has extensive experience in the development of novel cancer therapies and a shared commitment to the company’s vision for meaningful improvements in the lives of patients with cancer.
Clovis Oncology (NASDAQ: CLVS) is headquartered in Boulder, Colorado.
Please visit our website for more information, including additional office locations in the U.S. and Europe.
|
Open
|
oncology drug development and biotechnology
|
Open
|
5500 Flatiron Parkway
|
Boulder
|
CO
|
US
|
80301
|
|
Clovis Oncology
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:clvs
|
904367
|
Mar 22nd, 2024 12:00AM
|
Clovis Oncology
|
20K
|
89.00
|
Open
|
|
Mar 21st, 2024 11:14PM
|
Mar 22nd, 2024 06:22PM
|
Clovis Oncology is advancing the fight against cancer.
Founded in 2009, Clovis Oncology is a commercial-stage biotechnology company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Our pursuit is to improve the lives of people living with cancer. We believe our approach to precision medicine—to deliver the right drug to the right patient at the right time—represents the future of cancer therapy.
Our product development programs generally target specific subsets of cancer, and we seek to simultaneously develop, with partners, for those indications that require them, diagnostic tools intended to direct a compound in development to the patients most likely to benefit from their use. Through these collaborations, we have the flexibility to choose the most appropriate technology for each program, and the expertise to gain regulatory approvals and support global commercialization that will parallel Clovis’ regulatory and commercialization paths.
Clovis Oncology’s management team has extensive experience in the development of novel cancer therapies and a shared commitment to the company’s vision for meaningful improvements in the lives of patients with cancer.
Clovis Oncology (NASDAQ: CLVS) is headquartered in Boulder, Colorado.
Please visit our website for more information, including additional office locations in the U.S. and Europe.
|
Open
|
oncology drug development and biotechnology
|
Open
|
5500 Flatiron Parkway
|
Boulder
|
CO
|
US
|
80301
|
|
Clovis Oncology
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:clvs
|
904367
|
Mar 21st, 2024 12:00AM
|
Clovis Oncology
|
20K
|
89.00
|
Open
|
|
Mar 20th, 2024 11:25PM
|
Mar 21st, 2024 05:05PM
|
Clovis Oncology is advancing the fight against cancer.
Founded in 2009, Clovis Oncology is a commercial-stage biotechnology company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Our pursuit is to improve the lives of people living with cancer. We believe our approach to precision medicine—to deliver the right drug to the right patient at the right time—represents the future of cancer therapy.
Our product development programs generally target specific subsets of cancer, and we seek to simultaneously develop, with partners, for those indications that require them, diagnostic tools intended to direct a compound in development to the patients most likely to benefit from their use. Through these collaborations, we have the flexibility to choose the most appropriate technology for each program, and the expertise to gain regulatory approvals and support global commercialization that will parallel Clovis’ regulatory and commercialization paths.
Clovis Oncology’s management team has extensive experience in the development of novel cancer therapies and a shared commitment to the company’s vision for meaningful improvements in the lives of patients with cancer.
Clovis Oncology (NASDAQ: CLVS) is headquartered in Boulder, Colorado.
Please visit our website for more information, including additional office locations in the U.S. and Europe.
|
Open
|
oncology drug development and biotechnology
|
Open
|
5500 Flatiron Parkway
|
Boulder
|
CO
|
US
|
80301
|
|
Clovis Oncology
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:clvs
|
904367
|
Mar 20th, 2024 12:00AM
|
Clovis Oncology
|
20K
|
89.00
|
Open
|
|
Mar 19th, 2024 11:36PM
|
Mar 20th, 2024 07:06PM
|
Clovis Oncology is advancing the fight against cancer.
Founded in 2009, Clovis Oncology is a commercial-stage biotechnology company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Our pursuit is to improve the lives of people living with cancer. We believe our approach to precision medicine—to deliver the right drug to the right patient at the right time—represents the future of cancer therapy.
Our product development programs generally target specific subsets of cancer, and we seek to simultaneously develop, with partners, for those indications that require them, diagnostic tools intended to direct a compound in development to the patients most likely to benefit from their use. Through these collaborations, we have the flexibility to choose the most appropriate technology for each program, and the expertise to gain regulatory approvals and support global commercialization that will parallel Clovis’ regulatory and commercialization paths.
Clovis Oncology’s management team has extensive experience in the development of novel cancer therapies and a shared commitment to the company’s vision for meaningful improvements in the lives of patients with cancer.
Clovis Oncology (NASDAQ: CLVS) is headquartered in Boulder, Colorado.
Please visit our website for more information, including additional office locations in the U.S. and Europe.
|
Open
|
oncology drug development and biotechnology
|
Open
|
5500 Flatiron Parkway
|
Boulder
|
CO
|
US
|
80301
|
|
Clovis Oncology
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:clvs
|
904367
|
Mar 19th, 2024 12:00AM
|
Clovis Oncology
|
20K
|
89.00
|
Open
|
|
Mar 18th, 2024 11:02PM
|
Mar 19th, 2024 05:38PM
|
Clovis Oncology is advancing the fight against cancer.
Founded in 2009, Clovis Oncology is a commercial-stage biotechnology company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Our pursuit is to improve the lives of people living with cancer. We believe our approach to precision medicine—to deliver the right drug to the right patient at the right time—represents the future of cancer therapy.
Our product development programs generally target specific subsets of cancer, and we seek to simultaneously develop, with partners, for those indications that require them, diagnostic tools intended to direct a compound in development to the patients most likely to benefit from their use. Through these collaborations, we have the flexibility to choose the most appropriate technology for each program, and the expertise to gain regulatory approvals and support global commercialization that will parallel Clovis’ regulatory and commercialization paths.
Clovis Oncology’s management team has extensive experience in the development of novel cancer therapies and a shared commitment to the company’s vision for meaningful improvements in the lives of patients with cancer.
Clovis Oncology (NASDAQ: CLVS) is headquartered in Boulder, Colorado.
Please visit our website for more information, including additional office locations in the U.S. and Europe.
|
Open
|
oncology drug development and biotechnology
|
Open
|
5500 Flatiron Parkway
|
Boulder
|
CO
|
US
|
80301
|
|
Clovis Oncology
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:clvs
|
904367
|
Mar 18th, 2024 12:00AM
|
Clovis Oncology
|
20K
|
89.00
|
Open
|
|
Mar 17th, 2024 11:23PM
|
Mar 18th, 2024 06:50PM
|
Clovis Oncology is advancing the fight against cancer.
Founded in 2009, Clovis Oncology is a commercial-stage biotechnology company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Our pursuit is to improve the lives of people living with cancer. We believe our approach to precision medicine—to deliver the right drug to the right patient at the right time—represents the future of cancer therapy.
Our product development programs generally target specific subsets of cancer, and we seek to simultaneously develop, with partners, for those indications that require them, diagnostic tools intended to direct a compound in development to the patients most likely to benefit from their use. Through these collaborations, we have the flexibility to choose the most appropriate technology for each program, and the expertise to gain regulatory approvals and support global commercialization that will parallel Clovis’ regulatory and commercialization paths.
Clovis Oncology’s management team has extensive experience in the development of novel cancer therapies and a shared commitment to the company’s vision for meaningful improvements in the lives of patients with cancer.
Clovis Oncology (NASDAQ: CLVS) is headquartered in Boulder, Colorado.
Please visit our website for more information, including additional office locations in the U.S. and Europe.
|
Open
|
oncology drug development and biotechnology
|
Open
|
5500 Flatiron Parkway
|
Boulder
|
CO
|
US
|
80301
|
|
Clovis Oncology
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:clvs
|
904367
|
Mar 17th, 2024 12:00AM
|
Clovis Oncology
|
20K
|
89.00
|
Open
|
|
Mar 17th, 2024 12:14AM
|
Mar 17th, 2024 12:14AM
|
Clovis Oncology is advancing the fight against cancer.
Founded in 2009, Clovis Oncology is a commercial-stage biotechnology company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Our pursuit is to improve the lives of people living with cancer. We believe our approach to precision medicine—to deliver the right drug to the right patient at the right time—represents the future of cancer therapy.
Our product development programs generally target specific subsets of cancer, and we seek to simultaneously develop, with partners, for those indications that require them, diagnostic tools intended to direct a compound in development to the patients most likely to benefit from their use. Through these collaborations, we have the flexibility to choose the most appropriate technology for each program, and the expertise to gain regulatory approvals and support global commercialization that will parallel Clovis’ regulatory and commercialization paths.
Clovis Oncology’s management team has extensive experience in the development of novel cancer therapies and a shared commitment to the company’s vision for meaningful improvements in the lives of patients with cancer.
Clovis Oncology (NASDAQ: CLVS) is headquartered in Boulder, Colorado.
Please visit our website for more information, including additional office locations in the U.S. and Europe.
|
Open
|
oncology drug development and biotechnology
|
Open
|
5500 Flatiron Parkway
|
Boulder
|
CO
|
US
|
80301
|
|
Clovis Oncology
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:clvs
|
904367
|
Mar 16th, 2024 12:00AM
|
Clovis Oncology
|
20K
|
89.00
|
Open
|
|
Mar 15th, 2024 10:53PM
|
Mar 16th, 2024 06:37PM
|
Clovis Oncology is advancing the fight against cancer.
Founded in 2009, Clovis Oncology is a commercial-stage biotechnology company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Our pursuit is to improve the lives of people living with cancer. We believe our approach to precision medicine—to deliver the right drug to the right patient at the right time—represents the future of cancer therapy.
Our product development programs generally target specific subsets of cancer, and we seek to simultaneously develop, with partners, for those indications that require them, diagnostic tools intended to direct a compound in development to the patients most likely to benefit from their use. Through these collaborations, we have the flexibility to choose the most appropriate technology for each program, and the expertise to gain regulatory approvals and support global commercialization that will parallel Clovis’ regulatory and commercialization paths.
Clovis Oncology’s management team has extensive experience in the development of novel cancer therapies and a shared commitment to the company’s vision for meaningful improvements in the lives of patients with cancer.
Clovis Oncology (NASDAQ: CLVS) is headquartered in Boulder, Colorado.
Please visit our website for more information, including additional office locations in the U.S. and Europe.
|
Open
|
oncology drug development and biotechnology
|
Open
|
5500 Flatiron Parkway
|
Boulder
|
CO
|
US
|
80301
|
|
Clovis Oncology
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:clvs
|
904367
|
Mar 15th, 2024 12:00AM
|
Clovis Oncology
|
20K
|
89.00
|
Open
|
|
Mar 14th, 2024 11:52PM
|
Mar 15th, 2024 08:26AM
|
Clovis Oncology is advancing the fight against cancer.
Founded in 2009, Clovis Oncology is a commercial-stage biotechnology company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Our pursuit is to improve the lives of people living with cancer. We believe our approach to precision medicine—to deliver the right drug to the right patient at the right time—represents the future of cancer therapy.
Our product development programs generally target specific subsets of cancer, and we seek to simultaneously develop, with partners, for those indications that require them, diagnostic tools intended to direct a compound in development to the patients most likely to benefit from their use. Through these collaborations, we have the flexibility to choose the most appropriate technology for each program, and the expertise to gain regulatory approvals and support global commercialization that will parallel Clovis’ regulatory and commercialization paths.
Clovis Oncology’s management team has extensive experience in the development of novel cancer therapies and a shared commitment to the company’s vision for meaningful improvements in the lives of patients with cancer.
Clovis Oncology (NASDAQ: CLVS) is headquartered in Boulder, Colorado.
Please visit our website for more information, including additional office locations in the U.S. and Europe.
|
Open
|
oncology drug development and biotechnology
|
Open
|
5500 Flatiron Parkway
|
Boulder
|
CO
|
US
|
80301
|
|
Clovis Oncology
|
Health Care
|
Pharmaceuticals & Biotechnology
|